+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain



First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain



Journal of Pharmacology and Experimental Therapeutics 325(2): 641-645



Growing evidence supports the idea that in addition to their well established role in the immune system, chemokines might play a role in both normal and pathological brain function, and the chemokine network could interact with other neuromodulators. The chemokine stromal cell-derived growth factor (SDF)-1alpha/CXCL12, a member of the CXC chemokine family, was tested for its possible effect on the analgesic responses of the cannabinoid receptor agonist aminoalkylindole 4,5-dihydro-2-methyl-4-(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo-[3,2,1ij]quinolin-6-one [(+)-WIN 55,212-2, hereafter WIN 55,212-2] at the level of the periaqueductal gray (PAG), a brain region critical to the processing of pain signals, and a primary site of action of many analgesic compounds. The administration of WIN 55,212-2 (0.1-0.4 microg/microl) into the PAG resulted in antinociception in a dose-dependent manner. The selective cannabinoid (CB)1 antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride (SR 141716A; 1-10 microg) given into the PAG blocked the WIN 55,212-2-induced antinociception. In contrast, the selective CB2 antagonist N-[(1S)-endo-1,3,3-trimethyl bicyclo heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528; 10 microg) did not alter the WIN 55,212-2-induced antinociception. Pretreatment with SDF-1alpha/CXCL12 (100 ng) caused a reduction in antinociceptive responses of WIN 55,212-2. The inhibitory effect of SDF-1alpha/CXCL12 on WIN 55,212-2-induced antinociception was reversed by octahydrochloride [corrected] hydrate (AMD 3100) (10-50 ng), an antagonist of the SDF-1alpha/CXCL12, acting at its receptor, CXCR4. This study reports the first in vivo evidence of a functional interaction between chemokine and cannabinoid systems in the brain, showing that the activation of SDF-1alpha/CXCL12 receptors (CXCR4) in the PAG interferes with the analgesic effects of WIN 55212-2.

(PDF emailed within 0-6 h: $19.90)

Accession: 031454702

Download citation: RISBibTeXText

PMID: 18281594

DOI: 10.1124/jpet.107.135053


Related references

First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain (vol 325, pg 641, 2008). 2007

Cannabinoid interaction with brain reward systems. Nahas, G G, Sutin, K M, Harvey, D, Agurell, S Marihuana and medicine 187-205, 1999

Physiological evidence for interaction between the HIV-1 co-receptor CXCR4 and the cannabinoid system in the brain. British Journal of Pharmacology 157(7): 1225-1231, 2010

Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 54(4): 231-246, 2007

Solubilization of the cannabinoid receptor from rat brain and its functional interaction with guanine nucleotide-binding proteins. Molecular Pharmacology 43(1): 17-22, 1993

Differential modulations of striatal tyrosine hydroxylase and dopamine metabolism by cannabinoid agonists as evidence for functional selectivity in vivo. Neuropharmacology 62(7): 2328-2336, 2012

The Role of Chemokine and Glycosaminoglycan Interaction in Chemokine-Mediated Migration In Vitro and In Vivo. Methods in Enzymology 570: 309-333, 2016

Functional Interaction between the Dopamine and Melanocortin Systems of the Brain. Neuroscience and Behavioral Physiology 48(2): 213-219, 2018

Functional Interaction Between The Dopamine And Melanocortin Systems In The Brain. Rossiiskii Fiziologicheskii Zhurnal Imeni I.M. Sechenova 102(12): 1393-1405, 2018

In vivo evidence against functional significance of intrarenal prostaglandin i 2 angiotensin ii interaction in the rat. Kidney International 27(1): 270, 1985

Dopamine receptor subtypes: in vivo biochemical evidence for functional interaction. European Journal of Pharmacology 109(2): 297-300, 1985

Evidence for functional interaction between the HIV-1 Tat transactivator and the TATA box binding protein in vivo. Journal of Molecular Biology 250(2): 169-180, 1995

Functional interaction between serotonin and other neuronal systems: focus on in vivo microdialysis studies. Japanese Journal of Pharmacology 70(3): 203-205, 1996

Biochemical and pharmacological evidence of the interaction of serotonin with other aminergic systems in the brain. Garattini, Silvio, J F Pujol And R Samanin (Ed ) Monographs Of The Mario Negri Institute For Pharmacological Research Interactions Between Putative Neurotransmitters in The Brain Xv+415p Illus Raven Press: New York, N Y , Usa Isbn 0-89004-196-2 383-399, 1978

Spinal cord injuries induce changes in CB1 cannabinoid receptor and C-C chemokine expression in brain areas underlying circuitry of chronic pain conditions. Journal of Neurotrauma 28(4): 619-634, 2011